New methods to deliver IL-12 for treating solid tumors
Novel IL-12 Gene Delivery Vehicles for Transformation of Solid Tumors
This study is looking at new ways to help your immune system fight stubborn tumors by using a special treatment that delivers a helpful protein called IL-12 directly into the tumors, making them easier to treat and hopefully improving your chances of recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10754272 on NIH RePORTER |
What this research studies
This research focuses on improving cancer immunotherapy by developing innovative delivery systems for the cytokine IL-12, which can enhance the immune response against 'cold' solid tumors that typically resist treatment. The approach involves using novel gene delivery vehicles, including a self-replicating RNA system and a lentivirus targeting dendritic cells, to increase IL-12 production directly within tumors. By transforming these tumors from 'cold' to 'hot', the goal is to make them more responsive to existing therapies and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors that have low levels of immune cell infiltration and are currently unresponsive to standard immunotherapies.
Not a fit: Patients with tumors that are already responsive to existing immunotherapies or those with non-solid tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly enhance treatment options for patients with difficult-to-treat solid tumors, potentially leading to better survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in using IL-12 for cancer treatment, but this specific approach with novel delivery systems is relatively new and untested.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Pollack, Seth M — Northwestern University at Chicago
- Study coordinator: Pollack, Seth M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.